Skip to Content


Active Substance: doripenem
Common Name: doripenem
ATC Code: J01DH04
Marketing Authorisation Holder: Janssen-Cilag International NV
Active Substance: doripenem
Status: Withdrawn
Authorisation Date: 2008-07-25
Therapeutic Area: Cross Infection Bacterial Infections Pneumonia, Bacterial Pneumonia, Ventilator-Associated Urinary Tract Infections
Pharmacotherapeutic Group: Antibacterials for systemic use

Therapeutic Indication

Doribax is indicated for the treatment of the following infections in adults:

  • nosocomial pneumonia (including ventilator-associated pneumonia);
  • complicated intra-abdominal infections;
  • complicated urinary tract infections.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The marketing authorisation for Doribax has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.